Literature DB >> 33603583

Extended Infusion of Beta-Lactams Is Associated With Improved Outcomes in Pediatric Patients.

Tracy N Zembles, Rachael Schortemeyer, Evelyn M Kuhn, Glenn Bushee, Nathan E Thompson, Michelle L Mitchell.   

Abstract

OBJECTIVE: The pharmacokinetics of beta-lactam antibiotics favor administration via an extended infusion. Although literature supporting extended infusion beta-lactams exists in adults, few data are available to guide the practice in pediatrics. The purpose of this study was to compare clinical outcomes between extended and standard infusions in children.
METHODS: This retrospective chart analysis included hospitalized patients 0 to 18 years old who received at least 72 hours of cefepime, piperacillin-tazobactam, or meropenem between October 1, 2017, and March 31, 2019. Clinical outcomes of care included hospital length of stay, readmission within 30 days, and all-cause mortality.
RESULTS: A total of 551 patients (258 extended infusion, 293 standard infusion) met criteria for evaluation. Clinical outcomes among the entire population were similar. A subanalysis of select populations demonstrated decreased mortality in critical care patients (2.1% vs 19.6%, p = 0.006) and decreased 30-day readmission rates in bone marrow transplant patients (0% vs 50%, p = 0.012) who received the extended infusion compared with a standard infusion.
CONCLUSIONS: Outcomes were similar between extended and standard infusions in children. Subgroup analyses suggest a possible mortality benefit in the critically ill and decreased readmission rate in bone marrow transplant patients. Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org 2021.

Entities:  

Keywords:  beta-lactam; extended infusion; outcomes; pediatrics; pharmacokinetics

Year:  2021        PMID: 33603583      PMCID: PMC7887888          DOI: 10.5863/1551-6776-26.2.187

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  20 in total

1.  Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.

Authors:  Jesús Cotrina-Luque; Maria Victoria Gil-Navarro; Héctor Acosta-García; Eva Rocío Alfaro-Lara; Rafael Luque-Márquez; Margarita Beltrán-García; Francisco Javier Bautista-Paloma
Journal:  Int J Clin Pharm       Date:  2016-02

2.  Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations.

Authors:  Andrew A Udy; Julie M Varghese; Mahdi Altukroni; Scott Briscoe; Brett C McWhinney; Jacobus P Ungerer; Jeffrey Lipman; Jason A Roberts
Journal:  Chest       Date:  2012-07       Impact factor: 9.410

Review 3.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

4.  Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.

Authors:  Darren M Roberts; Jason A Roberts; Michael S Roberts; Xin Liu; Priya Nair; Louise Cole; Jeffrey Lipman; Rinaldo Bellomo
Journal:  Crit Care Med       Date:  2012-05       Impact factor: 7.598

5.  Conventional Versus Prolonged Infusion of Meropenem in Neonates With Gram-negative Late-onset Sepsis: A Randomized Controlled Trial.

Authors:  Abd Elazeez Shabaan; Islam Nour; Heba Elsayed Eldegla; Nehad Nasef; Basma Shouman; Hesham Abdel-Hady
Journal:  Pediatr Infect Dis J       Date:  2017-04       Impact factor: 2.129

6.  Implementing extended-infusion cefepime as standard of care in a children's hospital: a prospective descriptive study.

Authors:  Kristen R Nichols; Lauren C Karmire; Elaine G Cox; Michael B Kays; Chad A Knoderer
Journal:  Ann Pharmacother       Date:  2015-01-22       Impact factor: 3.154

Review 7.  Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis.

Authors:  Matthew E Falagas; Giannoula S Tansarli; Kazuro Ikawa; Konstantinos Z Vardakas
Journal:  Clin Infect Dis       Date:  2012-10-16       Impact factor: 9.079

8.  Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials.

Authors:  Jason A Roberts; Mohd-Hafiz Abdul-Aziz; Joshua S Davis; Joel M Dulhunty; Menino O Cotta; John Myburgh; Rinaldo Bellomo; Jeffrey Lipman
Journal:  Am J Respir Crit Care Med       Date:  2016-09-15       Impact factor: 21.405

Review 9.  The pharmacodynamics of beta-lactams.

Authors:  J D Turnidge
Journal:  Clin Infect Dis       Date:  1998-07       Impact factor: 9.079

10.  DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?

Authors:  Jason A Roberts; Sanjoy K Paul; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jeffrey Lipman
Journal:  Clin Infect Dis       Date:  2014-01-14       Impact factor: 9.079

View more
  3 in total

1.  A Review of Extended and Continuous Infusion Beta-Lactams in Pediatric Patients.

Authors:  Taylor A Imburgia; Michelle L Kussin
Journal:  J Pediatr Pharmacol Ther       Date:  2022-03-21

2.  Extended Infusion β-Lactams for the Treatment of Gram-Negative Bacteremia in Children.

Authors:  Tracy N Zembles; Evelyn M Kuhn; Nathan E Thompson; Michelle L Mitchell
Journal:  J Pediatr Pharmacol Ther       Date:  2022-09-26

3.  Advancing pediatric antimicrobial stewardship: Has pharmacodynamic dosing for gram-negative infections taken effect?

Authors:  Lauren M Puckett; Jason G Newland; Jennifer E Girotto
Journal:  Antimicrob Steward Healthc Epidemiol       Date:  2021-12-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.